Breaking News

Novo Nordisk Exits Inflammatory R&D

Will focus efforts on diabetes prevention and treatment

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk has decided to discontinue all R&D activities within inflammatory disorders and will increase efforts within diabetes prevention and treatment, obesity and diabetes complications.  ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters